The Effect of Bevacizumab on Corneal Neovascularization

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Instituto de Olhos de Goiania
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Corneal Neovascularization

• Stable lesion

Exclusion Criteria:

• Diabetes

• Autoimmune diseases